Late-Onset Medullary Thyroid Cancer in a Patient with a Germline RET Codon C634R Mutation
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Mathiesen, J.S.; Kroustrup, J.P.; Vestergaard, P.; Stochholm, K.; Poulsen, P.L.; Rasmussen, Å.K.; Feldt-Rasmussen, U.; Schytte, S.; Pedersen, H.B.; Hahn, C.H.; et al. Incidence and prevalence of multiple endocrine neoplasia 2A in Denmark 1901–2014: A nationwide study. Clin. Epidemiol. 2018, 10, 1479–1487. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Opsahl, E.M.; Brauckhoff, M.; Schlichting, E.; Helset, K.; Svartberg, J.; Brauckhoff, K.; Mæhle, L.; Engebretsen, L.F.; Sigstad, E.; Grøholt, K.K.; et al. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma. Thyroid 2016, 26, 1225–1238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wells, S.A.; Asa, S.L.; Dralle, H.; Elisei, R.; Evans, D.B.; Gagel, R.F.; Lee, N.; Machens, A.; Moley, J.F.; Pacini, F.; et al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid 2015, 25, 567–610. [Google Scholar] [CrossRef]
- Mulligan, L.M.; Kwok, J.B.; Healey, C.S.; Elsdon, M.J.; Eng, C.; Gardner, E.; Love, D.R.; Mole, S.E.; Moore, J.K.; Papi, L. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993, 363, 458–460. [Google Scholar] [CrossRef]
- Hofstra, R.M.; Landsvater, R.M.; Ceccherini, I.; Stulp, R.P.; Stelwagen, T.; Luo, Y.; Pasini, B.; Höppener, J.W.; van Amstel, H.K.; Romeo, G. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994, 367, 375–376. [Google Scholar] [CrossRef]
- Grey, J.; Winter, K. Patient quality of life and prognosis in multiple endocrine neoplasia type 2. Endocr. Relat. Cancer 2018, 25, T69–T77. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brandi, M.L.; Gagel, R.F.; Angeli, A.; Bilezikian, J.P.; Beck-Peccoz, P.; Bordi, C.; Conte-Devolx, B.; Falchetti, A.; Gheri, R.G.; Libroia, A.; et al. Consensus: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. J. Clin. Endocrinol. Metab. 2001, 86, 5658–5671. [Google Scholar] [CrossRef]
- Puñales, M.K.; Graf, H.; Gross, J.L.; Maia, A.L. RET Codon 634 Mutations in Multiple Endocrine Neoplasia Type 2: Variable Clinical Features and Clinical Outcome. J. Clin. Endocrinol. Metab. 2003, 88, 2644–2649. [Google Scholar] [CrossRef]
- Valdés, N.; Navarro, E.; Mesa, J.; Casterás, A.; Alcázar, V.; Lamas, C.; Tébar, J.; Castaño, L.; Gaztambide, S.; Forga, L. RET Cys634Arg mutation confers a more aggressive multiple endocrine neoplasia type 2A phenotype than Cys634Tyr mutation. Eur. J. Endocrinol. 2015, 172, 301–307. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schlumberger, M.; Pacini, F.; Tuttle, R.M. Medullary thyroid carcinoma. In Thyroid Tumors, 4th ed.; TCgraphite: Paris, France, 2015; pp. 355–395. [Google Scholar]
- Imai, T.; Uchino, S.; Okamoto, T.; Suzuki, S.; Kosugi, S.; Kikumori, T.; Sakurai, A. MEN Consortium of Japan. High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. Eur. J. Endocrinol. 2013, 168, 683–687. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Prejbisz, A.; Lenders, J.W.M.; Eisenhofer, G.; Januszewicz, A. Mortality Associated with Phaeochromocytoma. Horm. Metab. Res. 2013, 45, 154–158. [Google Scholar] [CrossRef] [PubMed]
- Russ, G.; Bonnema, S.J.; Erdogan, M.F.; Durante, C.; Ngu, R.; Leenhardt, L. European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. Eur. Thyroid. J. 2017, 6, 225–237. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Santoro, M.; Rosati, R.; Grieco, M.; Berlingieri, M.T.; D’Amato, G.L.; de Franciscis, V.; Fusco, A. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 1990, 5, 1595–1598. [Google Scholar]
- Donis-Keller, H.; Dou, S.; Chi, D.; Carlson, K.M.; Toshima, K.; Lairmore, T.C.; Howe, J.R.; Moley, J.F.; Goodfellow, P.; Wells, S.A. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 1993, 2, 851–856. [Google Scholar] [CrossRef]
- Piolat, C.; Dyon, J.-F.; Sturm, N.; Pinson, S.; Bost, M.; Jouk, P.-S.; Plantaz, D.; Chabre, O. Very early prophylactic thyroid surgery for infants with a mutation of the RET proto-oncogene at codon 634: Evaluation of the implementation of international guidelines for MEN type 2 in a single centre. Clin. Endocrinol. 2006, 65, 118–124. [Google Scholar] [CrossRef]
- Kloos (Chair), R.T.; Eng, C.; Evans, D.B.; Francis, G.L.; Gagel, R.F.; Gharib, H.; Moley, J.F.; Pacini, F.; Ringel, M.D.; Schlumberger, M.; et al. Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association. Thyroid 2009, 19, 565–612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Machens, A.; Dralle, H. Prophylactic Thyroidectomy in RET Carriers at Risk for Hereditary Medullary Thyroid Cancer. Thyroid 2009, 19, 551–554. [Google Scholar] [CrossRef] [PubMed]
- Schlumberger, M.; Bastholt, L.; Dralle, H.; Jarzab, B.; Pacini, F.; Smit, J.W.A.; The European Thyroid Association Task Force. 2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer. Eur. Thyroid J. 2012, 1, 5–14. [Google Scholar] [CrossRef] [Green Version]
- Giraudet, A.L.; Ghulzan, A.A.; Aupérin, A.; Leboulleux, S.; Chehboun, A.; Troalen, F.; Dromain, C.; Lumbroso, J.; Baudin, E.; Schlumberger, M. Progression of medullary thyroid carcinoma: Assessment with calcitonin and carcinoembryonic antigen doubling times. Eur. J. Endocrinol. 2008, 158, 239–246. [Google Scholar] [CrossRef] [PubMed]
- de Crea, C.; Raffaelli, M.; Maccora, D.; Carrozza, C.; Canu, G.; Fadda, G.; Bellantone, R.; Lombardi, C.P. Calcitonin measurement in fine-needle aspirate washouts vs. cytologic examination for diagnosis of primary or metastatic medullary thyroid carcinoma. Acta Otorhinolaryngol. Ital. 2014, 34, 399–405. [Google Scholar]
- Rohmer, V.; Vidal-Trecan, G.; Bourdelot, A.; Niccoli, P.; Murat, A.; Wemeau, J.L.; Borson-Chazot, F.; Schvartz, C.; Tabarin, A.; Chabre, O.; et al. Prognostic Factors of Disease-Free Survival after Thyroidectomy in 170 Young Patients with a RET Germline Mutation: A Multicenter Study of the Groupe Français d’Etude des Tumeurs Endocrines. J. Clin. Endocrinol. Metab. 2011, 96, E509–E518. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schreinemakers, J.M.J.; Vriens, M.R.; Valk, G.D.; de Groot, J.-W.B.; Plukker, J.T.; Bax, K.M.A.; Hamming, J.F.; van der Luijt, R.B.; Aronson, D.C.; Borel Rinkes, I.H.M. Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: A nationwide long-term follow-up study. World J. Surg. 2010, 34, 852–860. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Herfarth, K.K.-F.; Bartsch, D.; Doherty, G.M.; Wells, S.A.; Lairmore, T.C. Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Surgery 1996, 120, 966–974. [Google Scholar] [CrossRef]
- Filetti, S.; Durante, C.; Hartl, D.; Leboulleux, S.; Locati, L.D.; Newbold, K.; Papotti, M.G.; Berruti, A. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann. Oncol. 2019, 30, 1856–1883. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Prete, F.P.; Abdel-Aziz, T.; Morkane, C.; Brain, C.; Kurzawinski, T.R. Prophylactic thyroidectomy in children with multiple endocrine neoplasia type 2. J. Br. Surg. 2018, 105, 1319–1327. [Google Scholar] [CrossRef] [PubMed]
- Zou, H.-J.; Li, Y.-S.; Shan, Z.-Y. Genetic analysis and clinical investigation of a pedigree with multiple endocrine neoplasia type 2A: A case report. Oncol. Lett. 2016, 12, 2657–2659. [Google Scholar] [CrossRef] [Green Version]
Parametere | Reference Range | Before Surgery | After Surgery |
---|---|---|---|
Serum calcitonin (pg/mL) | 0.00–5.00 | 1596.00 | 5.81 |
Serum CEA (ng/mL) | 0.00–5.00 | 147.69 | 6.48 |
Serum calcium (mmol/L) | 2.10–2.60 | 2.46 | 2.32 |
Serum phosphorus (mg/dL) | 2.70–4.50 | 3.11 | 3.22 |
Serum intact PTH (ng/mL) | 15.00–68.30 | 103.8 | 67.9 |
Serum TSH (µIU/mL) | 0.35–4.94 | 0.6455 | 6.77 |
Serum Vitamin D (ng/mL) | 7.00–53.20 | 27.70 | 60.60 |
Serum CgA (ng/mL) | 19.40–98.10 | N/A | 58.70 |
Urine metanephrine (µg/24 h) test I/test II | 74.00–297.00 | 251.69/304.37 | 169.59 |
Urine normetanephrine (µg/24 h) test I/test II | 105.00–354.00 | 321.89/322.74 | 264.15 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Walczyk, A.; Zgubieński, K.; Chmielewski, G.; Hińcza-Nowak, K.; Kowalik, A.; Jaskulski, J.; Kowalska, A. Late-Onset Medullary Thyroid Cancer in a Patient with a Germline RET Codon C634R Mutation. Diagnostics 2021, 11, 1448. https://doi.org/10.3390/diagnostics11081448
Walczyk A, Zgubieński K, Chmielewski G, Hińcza-Nowak K, Kowalik A, Jaskulski J, Kowalska A. Late-Onset Medullary Thyroid Cancer in a Patient with a Germline RET Codon C634R Mutation. Diagnostics. 2021; 11(8):1448. https://doi.org/10.3390/diagnostics11081448
Chicago/Turabian StyleWalczyk, Agnieszka, Kajetan Zgubieński, Grzegorz Chmielewski, Kinga Hińcza-Nowak, Artur Kowalik, Jarosław Jaskulski, and Aldona Kowalska. 2021. "Late-Onset Medullary Thyroid Cancer in a Patient with a Germline RET Codon C634R Mutation" Diagnostics 11, no. 8: 1448. https://doi.org/10.3390/diagnostics11081448